Davita (NYSE:DVA) updated its FY20 earnings guidance on Thursday. The company provided EPS guidance of $6.25-$6.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.11. The company issued revenue guidance of $11.5-$11.7 billion, compared to the consensus revenue estimate of $11.70 billion.Davita also updated its FY 2020
After-Hours guidance to 6.25-6.75 EPS.
NYSE:DVA traded down $3.73 during trading hours on Friday, reaching $87.39. 1,830,827 shares of the company traded hands, compared to its average volume of 736,563. The business’s 50-day moving average price is $81.67 and its two-hundred day moving average price is $79.28. The stock has a market capitalization of $10.64 billion, a P/E ratio of 13.78, a P/E/G ratio of 1.56 and a beta of 1.20. Davita has a 1 year low of $53.51 and a 1 year high of $92.16. The company has a current ratio of 1.81, a quick ratio of 1.77 and a debt-to-equity ratio of 5.24.
Davita (NYSE:DVA) last released its quarterly earnings results on Thursday, July 30th. The company reported $1.95 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.65. The business had revenue of $2.88 billion during the quarter, compared to analyst estimates of $2.91 billion. Davita had a return on equity of 40.83% and a net margin of 7.20%. As a group, equities analysts anticipate that Davita will post 6.49 EPS for the current year.
In other news, Director Pamela M. Arway sold 599 shares of the stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $78.90, for a total value of $47,261.10. Following the completion of the transaction, the director now owns 19,239 shares in the company, valued at approximately $1,517,957.10. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Paul J. Diaz sold 5,763 shares of the company’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $82.22, for a total transaction of $473,833.86. Following the completion of the sale, the director now directly owns 15,749 shares in the company, valued at approximately $1,294,882.78. The disclosure for this sale can be found here. Insiders have sold 12,109 shares of company stock worth $989,903 in the last 90 days. 1.00% of the stock is owned by company insiders.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Story: Understanding Market Liquidity
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.